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Increased bone strontium levels in hemodialysis patients with marked metabolic disturbances that result in the devel-
osteomalacia. opment of renal osteodystrophy, the spectrum of which
Background. In this study, we report on the association be- covers two general types of bone disease: a high turnovertween increased bone strontium levels and the presence of
disease exemplified by either osteitis fibrosa or mild sec-osteomalacia in end-stage renal failure patients treated by he-
ondary hyperparathyroidism, and the low turnover le-modialysis.
Methods. We performed a histologic examination and deter- sions characterized by osteomalacia and adynamic bone
mined the strontium content and strontium/calcium ratios in disease. Mixed or transitional disorders displaying the
bone biopsies of 100 hemodialysis patients recruited from vari-
histologic features of both low and high turnover lesionsous centers all over the world. Aside from the bone strontium
may also be present. The mechanisms underlying theconcentration, the bone aluminum content was assessed. The
bone zinc concentration, a nonrelevant element for bone toxic- development of these bone diseases are multifactorial
ity, was also measured. and still controversial [1, 2]. The initial derangements
Results. Bone strontium levels and bone strontium/calcium
induced by the failing endocrine and excretory functionsratios were increased in subjects with osteomalacia when com-
of the kidney are rather uniform among chronic renalpared with those with the other types of renal osteodystrophy.
Bone strontium and bone calcium levels correlated with each failure patients. However, other factors such as the
other. The slope of the linear regression curve correlating these prominence of vitamin D deficiency, medication, expo-
parameters was much steeper in the osteomalacic group (Y 5 sure to aluminum, and dialysis modalities influence the2.22X 2 120) as compared with the other types of renal osteo-
bone abnormalities that develop in ESRF patients whodystrophy (Y 5 0.52X 2 5.7). Within the group of patients
require maintenance dialysis [3–5]. In a distinct numberwith osteomalacia, bone strontium levels also significantly cor-
related with the bone aluminum content (r 5 0.72, P 5 0.018). of chronic renal failure patients, the etiology of their
No such correlation was found for the other types of renal bone disease remains unknown.
osteodystrophy. The bone zinc concentration of subjects with
Because of the impaired renal function, medication,normal renal function did not differ significantly from the val-
and the use of contaminated dialysis and parenteral flu-ues noted for the various types of renal osteodystrophy taken
as separate groups, nor could increased bone zinc concentra- ids, trace elements may accumulate in dialysis patients
tions be associated with a particular bone lesion. [6]. The association between bone aluminum accumula-
Conclusions. Our data demonstrate an association between tion and the development of osteomalacia and to a lessosteomalacia and increased bone strontium concentrations in
extent adynamic bone disease has been established indialysis patients. Further studies are warranted to establish
whether strontium plays either a primary, secondary, or con- these subjects [3, 7, 8]. The extent to which other trace
tributive role in the development of the latter type of renal elements may also interfere with the bone metabolism
osteodystrophy. of dialysis patients is unknown.
In view of (1) the striking physicochemical similari-
End-stage renal failure (ESRF) patients, especially ties of strontium with calcium, (2) the element’s poten-
those treated by chronic maintenance dialysis, exhibit tial to accumulate in dialysis patients [9, 10], (3) the re-
ported interference of strontium with the biosynthesis
of 1a,25-(OH)2D3 and calcium absorption [11, 12], andKey words: renal osteodystrophy, bone histology, mineralization, trace
metal, dialysis. (4) the previously described effects on bone formation,
mineralization, and resorption, as evidenced in experi-
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By means of a recently developed analytical electro- elements under study. Only plastic material was used for
sample storage and preparation [20]. Bone samples ofthermal atomic absorption spectrometric method [16],
we determined the bone strontium levels in 100 biopsies subjects with normal renal function were taken at au-
topsy following the same procedure.of hemodialysis patients from various centers in several
countries and correlated these with the different types All bone samples were divided in two pieces. One part
was put in Burkhardt’s solution for 24 hours, and it wasof renal osteodystrophy.
then transferred to 70% ethanol and stored at 48C until
further processing for histologic/histochemical examina-
METHODS
tion. The second part was weighed directly after sampling
Patients and stored at 2208C until chemical analysis, that is, stron-
tium, aluminum, zinc, and calcium measurement.Transiliac bone biopsies were taken in 100 dialysis pa-
tients from different centers in various geographic areas:
Laboratory analysesBelgium (N 5 46), Greece (N 5 39), Czechia (N 5 7),
Argentina (N 5 3), and Egypt (N 5 5). Bone biopsies Bone analysis. Before measurement for chemical anal-
ysis, 20 to 500 mg of the human transiliac bone biopsieswere taken within a period of two years in the frame of
studies on the noninvasive diagnosis of adynamic and were digested at 90 to 1008C in 1 to 2 mL of nitric acid
(Suprapurt; Merck, Darmstadt, Germany) in stopperedaluminum-related bone disease [17, 18]. There were 48
males (48%) and 52 females with a mean 6 SD age of polytetrafluoroethylene test tubes for at least three to
four hours until a clear digest was obtained [21]. According58.8 6 13.2 years and a mean 6 SD time on dialysis of
5.19 6 4.17 years. Data on phosphate-binding therapy to the sample weight, the clear digest was adjusted to
either 10, 25, or 50 mL with doubly distilled water inwere available for 89 patients and consisted of CaCO3
in 33 patients, 31 patients received Al(OH)3, while 21 polypropylene volumetric flasks and subsequently trans-
ferred to stoppered polystyrene test tubes for storage atpatients took a combination of CaCO3 and Al(OH)3.
Four patients did not receive any phosphate binder at 2208C until analysis. The elements under study were
determined in the same bone digestion liquid by atomicall. Some (44.2%) of the patients received vitamin D. No
differentiation was made between the various vitamin D absorption spectrometry. For the determination of cal-
cium, we used flame atomic absorption spectrometryanalogues.
The indications for performing a bone biopsy were (Perkin-Elmer Model 3110; Perkin-Elmer, Norwalk, CT,
USA). With this method, bone digestion liquids werediverse: suspicion of aluminum intoxication, abnormal
levels of parathyroid hormone (iPTH; either high or diluted 1/500 in doubly distilled water containing 1 g/L
of lanthanum, which was added to overcome ionizationlow), diagnostic work-up before parathyroidectomy, a
low bone-alkaline phosphatase level, or a combination and phosphate interferences. Strontium, aluminum, and
zinc were measured by means of electrothermal atomicof either of these pathologies. To determine the bone
formation rate (BFR) and to perform histologic classifica- absorption spectrometry with Zeeman background cor-
rection (Perkin-Elmer Model 3030; Graphite Furnacetion, a double tetracyclin labeling was performed prior
to biopsy that followed a standardized procedure [19]. HGA 600) using or adapting previously described meth-
odologies [16, 21, 22].Criteria for classification of the different types of bone
disease are outlined later in this article. Histologic data as well as dynamic parameters are
reported according to the standardized nomenclatureBone samples were also taken postmortem in 10 sub-
jects known to have had a normal renal function and no and definitions [23]. Undecalcified, 4 mm thick human
bone sections were stained according to Goldner forhistory of bone disease or endocrine or metabolic disease
or drug intake interfering with bone metabolism. Their descriptive histology and with Aluminont for aluminum
staining. Aluminum staining was not performed in threemean age was 56.9 6 23.7 years and was not significantly
different (P 5 0.75) from that of the dialysis population. patients with adynamic bone disease (ABD), one with
mixed lesion, and two with hyperparathyroidism. TenTwo out of the 10 normal patients were female. All of
these subjects presented a normal bone histology. micrometer sections were mounted unstained in 10%
glycerol and examined by fluorescence microscopy for
Bone biopsy the evaluation of tetracyclin labels [24].
The following histologic variables were determinedBone biopsies of dialysis patients were taken under
local anesthesia using a Bordier-Meunier needle. To re- for trabecular bone: (1) total bone area (%), the area
of trabecular bone, including both mineralized bone andduce the risk for contamination, the use of reagents was
kept minimal, and every item used from the moment of unmineralized bone matrix (osteoid), expressed as a per-
centage of the total tissue area; (2) osteoid area (%),sampling until analysis was regarded as a potential source
of contamination and was checked to verify that it did the area of unmineralized bone matrix expressed as a
percentage of the total bone area; (3) osteoid surface (%),not to contain or leach any detectable amount of the
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Table 1. Clinical/personnel data of the various study groups
Age Sex Time in dialysis Vitamin D
Lesion N years M/F years intake %
ABD 35 62.469.2 18/17 3.763.3 41
MX 21 60.0612.4 8/13 5.565.6 45
N 13 64.3612.8 5/8 5.763.0 31
HPTH 21 51.2615.9a 11/10 7.364.2b 29
OM 10 53.0612.9 6/4 4.162.4 70c
Abbreviations are: ABD, adynamic bone disease; MX, mixed lesion; N, normal
histology; HPTH, hyperparathyroidism; OM, osteomalacia.
aP , 0.05 vs. ABD and N
bP , 0.05 vs. ABD
cP , 0.05 vs. all other groups
Fig. 1. Distribution of the various types of renal osteodystrophy of the
dialysis population under study.
Statistics
A comparison between groups of the various parame-
ters under study assessed in bone or serum was done by
the percentage of the trabecular bone surface covered means of either Kruskal-Wallis or one-way analysis of
by osteoid; (4) osteoid thickness (mm), the mean width of variance (ANOVA), followed by the Bonferroni test
surface osteoid seams obtained by dividing the measured when more than two groups were considered. A compari-
osteoid area, in mm2, by the length in mm, of trabecular son of the bone strontium concentration in patients taken
surface covered by osteoid; (5) eroded surface (%), the vitamin D versus patients without vitamin D intake and
percentages of trabecular bone surface characterized by males versus females was done by means of the Mann–
the presence of scalloped bone resorptive lacunae; (6) Whitney rank sum test. A comparison of the percentage
double tetracyclin-labeled surface (%), the percentage of patients taking vitamin D in the various study groups
of trabecular bone surfaces that exhibited double bands was done by chi-square analysis. A P value , 0.05 was
of tetracyclin fluorescence; (7) mineral apposition rate considered to be significant at a two-tailed level. The
(mm/day), determined by dividing the width of separation SPSS statistical software was used. Bone analyte concen-
of double tetracyclin labels by the time interval between trations are expressed in mg/g wet weight. As a general
the administration of the two labels; (8) BFR (mm2/mm2/ rule, to compare wet weight measurements of the present
day), defined as the area of bone formed per unit area study with literature data using dry or ash weight mea-
of existing trabecular bone per day; and (9) mineraliza- surements, the conversion of 10 g wet 5 6 g dry 5 3 g
tion lag time (days), calculated by dividing the mean ash should be used. Results are expressed in either mean 6
osteoid thickness by the mineral bone apposition rate. SD or median (range; Box-Whisker plots, serum bio-
The different types of renal osteodystrophy were diag- chemistry). The analyte/Ca ratio was calculated to allow
nosed according to the amount of osteoid, the presence correction for bone density. Relationships between vari-
of fibrosis, and the BFR [19]. Normal histology was de- ables were assessed by linear regression analysis.
fined as an osteoid area of ,12%, no fibrosis, and BFR
in 97 to 613 mm2/mm2/day range. Hyperparathyroidism
RESULTSwas an osteoid area of ,12%, no fibrosis (mild) with
fibrosis (osteitis fibrosa), and BFR .613 mm2/mm2/day; Histologic and histomorphometric examination of 100
in the present study, osteitis fibrosa and mild hyperpara- bone biopsies revealed that our study patients repre-
thyroidism were considered as one group. Osteomalacia sented various types of renal osteodystrophy (Fig. 1).
was an osteoid area of .12%, no fibrosis, BFR ,97 mm2/ Clinical and biochemical data corresponding with the
mm2/day. Adynamic bone disease was an osteoid area different bone lesions are presented in Tables 1 and 2.
of ,12%, no fibrosis, BFR ,97 mm2/mm2/day. Mixed Chemical bone analysis by Zeeman atomic absorption
lesion was an osteoid area .12%, with fibrosis. spectrometry indicated the bone strontium/calcium ratio
Biochemical serum analysis. Serum iPTH levels were in the overall dialysis population to differ significantly
determined by means of a two-side immunoradiometric from that noted in subjects with normal renal function
assay (IRMA; Nichols Institute, San Juan Capistrano, (0.49 3 1023 6 0.27 3 1023 vs. 0.29 3 1023 6 0.08 3
CA, USA). For the measurement of serum osteocalcin 1023, P 5 0.0048). Within the dialysis population, both
(OC), the radioimmunoassay from Incstar (Stillwater, bone strontium levels and strontium/calcium ratios in
MN, USA) was used. Bone alkaline phosphatase was patients with osteomalacia (mean 6 SD; 91 6 51 mg/g,
determined by an agarose gel electrophoretic method 0.92 3 1023 6 0.41 3 1023) were significantly (P , 0.0001)
higher than the values noted in all other types of renaldescribed by Van Hoof et al [25].
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Table 2. Biochemical data [median (range)] of the various study groups
Serum
Type of bone lesion iPTH pg/mL BAP U/L OC ng/mL
ABD 91 (1–367) 20 (9–636) 7.3 (1.5–20.8)
MX 353 (91–1152)a 125 (22–1919)c 17.1 (3.2–34.3)d
N 200 (31–650) 34 (12–119) 10.0 (6.9–21.3)
HPTH 797 (180–2240)b 184 (30–1604) 19.0 (5.6–58.3)e
OM 109 (8–318) 50 (11–715) 11.5 (3.4–23.1)
Abbreviations are: ABD, adynamic bone disease; MX, mixed lesion; N, normal histology; HPTH, hyperparathyroidism, OM, osteomalacia; BAP, bone alkaline
phosphatase; OC, osteocalcin; iPTH, intact parathormone.
aP , 0.005 vs. ABD
bP , 0.001 vs. ABD, MX, N, OM
cP , 0.05 vs. ABD
dP , 0.005 vs. ABD
eP , 0.005 vs. ABD, N; P , 0.05 vs. OM
osteodystrophy considered as a single group (45 6 31 as separate groups, nor could increased bone zinc con-
mg/g, 0.45 3 1023 6 0.22 3 1023; Fig. 2A). Taking all centration be associated with any type of renal osteodys-
types of renal osteodystrophy separately, it was found trophy (Fig. 3B).
that both the strontium concentration and strontium/ Within the group of patients with osteomalacia, bone
calcium ratio in osteomalacic bone were significantly in- strontium levels significantly correlated with the bone
creased (P , 0.05) as compared with all other types of aluminum content (Y 5 0.88X 1 41.6, r 5 0.721, P 5
renal osteodystrophy: normal histology (30 6 24 mg/g, 0.018), while this was not the case for the other types
0.33 3 1023 6 0.13 3 1023), hyperparathyroid bone dis- of renal osteodystrophy. Within the dialysis population,
ease (48 6 32 mg/g, 0.44 3 1023 6 0.28 3 1023), adynamic both strontium and aluminum significantly correlated
bone disease (48 6 25 mg/g, 0.44 3 1023 6 0.14 3 1023), with the osteoid area [r 5 0.300, P 5 0.003 (strontium);
and mixed bone lesion (45 6 42 mg/g, 0.47 3 1023 6 r 5 0.561, P , 0.0001 (aluminum)], whereas strontium
0.28 3 1023; Fig. 2B). (not aluminum) also correlated with the mineralization
As expected, the bone aluminum/calcium ratio in the lag time (r 5 0.285, P 5 0.006).
dialysis patients (0.34 3 1023 6 0.50 3 1023) significantly In the patients with osteomalacia, as well as in those
differed from the values noted in the subjects with nor- presenting the other types of renal osteodystrophy, a
mal renal function (P , 0.0001; 0.018 3 1023 6 0.009 3 significant association was found between the bone
1023). Considering the hemodialysis population, the strontium and bone calcium content (r 5 0.78, P 5 0.008,
bone aluminum/calcium ratios of the various groups be- and r 5 0.68, P , 0.0001, respectively; Fig. 4). However,
haved in a less specific way compared with what was when the slopes of the linear regression curves correlat-
noted for strontium. Indeed, whereas an increased stron- ing bone strontium (Y) and bone calcium (X) concentra-
tium/calcium ratio could be associated with a single type
tions were compared with each other, the curve was
of renal osteodystrophy, that is, osteomalacia, the bone
much steeper in the osteomalacic group (Y 5 2.22X 2aluminum/calcium ratio differed significantly (P , 0.05)
120; Fig. 4A) than noted for the patients presenting theonly between the patients presenting the mixed lesion
other types of renal osteodystrophy (Y 5 0.52X 2 5.7;(0.58 3 1023 6 0.93 3 1023) versus those having adynamic
Fig. 4B).bone disease (0.17 3 1023 6 0.21 3 1023; Fig. 3A). Posi-
Patients with osteomalacia came from various regions,tive staining (.0%) for aluminum was not only associ-
that is, Belgium (N 5 3), Egypt (N 5 4), Argentina (N 5ated with osteomalacia (6 out of 10 patients; range of
2), and Greece (N 5 1). Furthermore, it was noted thatbone surface stained positive 0 to 93.4%) but also with
the bone strontium (r 20.28, P 5 0.009) and strontium/the other types of renal osteodystrophy: adynamic bone
calcium ratio (r 20.31, P 5 0.003) decreased with age(11 out of 32; 0 to 45%), mixed lesion (9 out of 20; 0 to
when calculated for the entire study population. No rela-34.3%), normal histology (8 out of 13; 0 to 31.0%), and
tionship was found between the bone strontium contenthyperparathyroidism (4 out of 19; 0 to 29.7%).
or strontium/calcium ratio with sex or vitamin D intake.As a nonrelevant element for bone toxicity and to
With regard to the latter, it should be mentioned, how-check whether the observations for strontium were not
ever, that the percentage of patients taking vitamin Dmainly due to the patients’ uremic state, the bone zinc
differed between groups (P 5 0.033) and was signifi-concentration was also assessed. The bone zinc concen-
cantly (P , 0.05) higher in the osteomalacic group astration and zinc/calcium ratios of subjects with normal
compared with all other types of renal osteodystrophyrenal function did not differ significantly from the values
found for the various types of renal osteodystrophy taken (Table 1).
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Fig. 3. (A) Bone aluminum/calcium ratio in function of the various
types of renal osteodystrophy in the dialysis population and subjects
with normal renal function. Statistical analysis revealed the bone alumi-
num/calcium ratio to be significantly (P , 0.05) elevated as compared
with subjects with normal renal function (P , 0.05). Within the dialysis
population, the bone aluminum/calcium ratio significantly (P 5 0.019)
differed between the various types of renal osteodystrophy. Post hoc
pair-wise comparison only revealed significant differences between the
mixed lesion and adynamic bone (P , 0.05). From left to right, adynamic
bone disease, mixed disease, normal histology, hyperparathyroidism,
Fig. 2. (A) The bone strontium/calcium ratio in dialysis patients with osteomalacia, and normal renal function are shown. (B) The bone zinc/
osteomalacia (OM) versus the total group of patients presenting the calcium ratio did not differ significantly between the various types of
other types of renal osteodystrophy (P , 0001). (B) Bone strontium/ renal osteodystrophy and individuals with normal renal function. Also,
calcium ratio of dialysis patients with osteomalacia versus the other there was no association between the bone zinc/calcium ratio and any
types of renal osteodystrophy and the ratio noted in subjects with type of renal osteodystrophy.
normal renal function. Statistical analysis revealed the bone strontium/
calcium ratio in patients with osteomalacia to be significantly (P , 0.05)
elevated as compared with all other groups. From left to right, adynamic
bone disease, mixed disease, normal histology, hyperparathyroidism, testinal absorption represents the main route of entry ofosteomalacia, and normal renal function are shown.
strontium in nondialyzed individuals. As for calcium,
the fractional absorption of this “bone seeking” element
seems to depend strongly on vitamin D status [15, 27].
DISCUSSION Although a substantial amount of data have been pub-
lished in the 1960s in connection with protective mea-In the geosphere, strontium occurs in relatively high
amounts. Its concentration in the earth crust varies around sures against radiostrontium [28–30], information on the
element’s metabolism in ESRF patients is lacking. It is450 p.p.m., ranking as the 15th element in the order of
crustal abundance [26]. Although there are some indica- clear that strontium, which is mainly excreted by the
kidney, might accumulate and perhaps exert some ad-tions for strontium to be an essential element for bone
calcification, clear-cut evidence is still lacking. Gastroin- verse effects in these subjects.
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Fig. 4. Relationships between the bone cal-
cium and bone strontium concentration in pa-
tients with osteomalacia (A) and those present-
ing the other types of renal osteodystrophy (B).
A striking difference was noted between the
slopes of both regression curves. Symbols are:
(s) adynamic bone disease; (d) mixed dis-
ease; (h) normal histology; (j) osteitis fi-
brosa; (n) osteomalacia. In panel A, r 5 0.775;
P 5 0.008; Y 5 2.22x 2 120. In panel B, r 5
0.677; P 5 0.0001; Y 5 0.52x 2 5.7.
In the present study, to our knowledge for the first strontium on the 1a,25-(OH)2D3 biosynthesis has been
formulated [11, 35]. This physiopathological mechanism,time, strontium levels were assessed in duplicates of bone
biopsies with known histologic and histomorphometric however, cannot be taken into account to explain our
observations in ESRF. Indeed, in the presence of a dra-characteristics that were obtained from ESRF patients
treated by hemodialysis. Considering the bone stron- matically reduced renal mass, 1a-hydroxylase activity is
clearly reduced. Aside from its effect on bone mineraliza-tium/calcium ratio, a significantly increased overall value
was noted in ESRF patients as compared with that of tion, it has to be mentioned that strontium, as demon-
strated in rats with normal renal function, may also affectsubjects with normal renal function. A more interesting
observation was made within the dialysis population it- osteoblast function, osteoid deposition, and bone resorp-
tion in a complex, dose-dependent way [13, 15]. Becauseself. Here, by classifying the patients according to the
five different types of renal osteodystrophy, a distinct of their ability to uncouple bone resorption from bone
formation, the potential use of strontium compounds inincrease in the bone strontium concentration as well
as the strontium/calcium ratio was observed in those the treatment of osteoporosis has been considered [36].
As early as 1973, Rudolf, Alfrey, and Smythe usedindividuals presenting the histologic features of osteoma-
lacia. This type of renal bone disease is characterized by x-ray fluorescence and found distinctly increased (five-
fold to eightfold) strontium concentrations in skeletalan increased amount of osteoid resulting from a deficient
mineralization, as evidenced by an increased mineraliza- muscle of dialyzed uremics, as compared with those of
nondialyzed individuals and controls [37]. They sug-tion lag time, reduced double-labeled surface, mineral
apposition rate, and BFR. To our knowledge, no such gested that increased strontium levels originate from the
use of untreated high strontium tap water used to pre-relationship has previously been demonstrated in ESRF
patients enrolled in a chronic hemodialysis program. In- pare the dialysis fluids, and promoted the idea that stron-
tium might play some role in renal osteodystrophy.terestingly, in a recent epidemiological study in children
with normal renal function, a link between a high soil The present bone biopsy study is limited in its ability
to demonstrate a causal relationship between increasedstrontium and increased prevalence of “rickets,” diag-
nosed on the basis of a series of clinical symptoms such bone strontium levels and the development of osteoma-
lacia. Support for such an association is provided by theas bone deformities, craniotabes, rachitic rosary, delayed
closure of fontanels, and conspicuous bulging at the results of a worldwide epidemiological study recently
published by our group, where we noted large country-wrists, has been suggested [31]. Experimentally, it has
been shown that the administration of the element to to-country and center-to-center variations in the serum
strontium levels of dialysis patients. In these patients,animals with normal renal function may result in a bone
lesion with a histologic resemblance to that seen in “vita- high serum strontium levels appeared to originate from
the use of high strontium dialysis fluids, resulting frommin D-deficient rickets” [32]. The particular form of
rickets produced by strontium, the so-called strontium- the addition of contaminated concentrates [38]. It should
be noted that diet (for example, drinking water, cereals,induced rickets [33, 34], however, differs from calcium-
or phosphorus-deficiency rickets in that vitamin D sup- grains, seafood), medication, environment, among other
factors, to a certain extent may also be responsible forplements do not correct the lesion [34, 35]. As a possible
explanation for this observation, an inhibitory effect of the accumulation of the element in the ESRF patient.
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In the present study, no significant correlation could be interfering with the synthesis of collagen, that is, osteo-
blastic activity. Hence, strontium most probably directlyfound between bone strontium levels and vitamin D in-
affects bone mineralization by interference with the pro-take. The percentage of patients taking vitamin D ana-
cess of calcification. The possibility that an increasedlogues, however, was significantly higher in the osteoma-
deposition of strontium occurred secondary to the pres-lacia group as compared with all other types of renal
ence of osteomalacia or the patients’ uremic state canosteodystrophy. Although such a finding is difficult to
be further weakened by our data on bone zinc, as nointerpret, it is well known that pathways of gastrointesti-
variation in concentration was noted for any type ofnal absorption of strontium and calcium are identical
renal osteodystrophy and the levels found in subjects[27]. In this context, our recent findings of a multicenter
with normal renal function.study demonstrating serum calcium levels to be signifi-
In the present study, we have not been able to ultra-cantly lower in patients with high serum strontium (.100
structurally localize strontium in bone at the concentra-mg/L) are worth being mentioned [38].
tion in which the element is present in dialysis patientsEvidence for a causal role of strontium in the develop-
with osteomalacia. In strontium-loaded rats, however,ment of osteomalacia has recently been presented from
both histochemical and EPXMA analysis revealed thean experimental study in which the dietary administra-
element to be present in calcified bone, mainly in closetion of strontium in a chronic renal failure rat model
proximity to the osteoid calcification front, suggesting aresulted in the development of osteomalacic lesions in
potential interference with bone mineralization [39]. Inall of the animals, as judged by established histologic
previous studies, the element has been attributed ancriteria [39]. An additional interesting finding was that
inhibitory role in nucleation and hydroxyapatite growth,rats loaded solely with aluminum developed adynamic
the latter being due to the element’s ability to easilybone disease, whereas those receiving both strontium
enter the hydroxyapatite lattice where it competes withand aluminum developed either adynamic bone or a
calcium and slows down crystal growth because of itsmore severe form of osteomalacia. Here, the observation
larger size [41]. The interaction of strontium with theof a severe mineralization defect in rats receiving both
calcium incorporation in bone might also, to a certainelements points toward a possible synergy between
extent, be reflected by the differences in the slopes ofstrontium and aluminum in the development of osteoma-
the linear regression curves correlating bone calciumlacia. In this context, the striking correlation noted in the
with bone strontium levels in the osteomalacic patientspresent study between the bone strontium and aluminum
versus those presenting the other types of renal osteodys-content in dialysis patients with osteomalacia, as opposed
trophy. Note, however, that based on these figures, theto those presenting the other types of renal osteodystro-
opposite, that is, a preferential accumulation of stron-
phy, is of particular interest. Studies are being performed tium in osteomalacic bone, cannot be excluded.
to check whether or not osteomalacic lesions in the rem- In conclusion, data of the present study indicate that
nant kidney model may also be induced at more physio- strontium may accumulate in ESRF patients treated by
logically relevant dosages. Here, it should be noted that hemodialysis. The deposition of the element in bone of
comparing the effects of strontium on bone at a given these subjects is associated with the presence of osteoma-
dose in animals versus dialysis patients is complex in lacia. The extent to which strontium plays either a causal,
view of the substantial differences that exist between contributive, or secondary role in the development of
both species in terms of bone and metabolic turnover, this particular type of renal osteodystrophy is not yet
residual renal function, gastrointestinal absorption, par- clear and is under current investigation.
enteral uptake, and so forth.
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